El cáncer de pulmón de células pequeñas (SCLC): en la puerta de las terapias dirigidas
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.El tratamiento del cáncer de pulmón de células pequeñas está avanzando más allá de la quimioterapia. Las nuevas terapias dirigidas, como las dirigidas a DLL3 y B7-H3, ofrecen una mejor supervivencia y redefinen la atención para los pacientes con este desafiante tumor neuroendocrino.
Área De La Ciencia
- Oncología, específicamente tumores torácicos y tumores neuroendocrinos.
- Investigación traslacional aplicando subtipos moleculares y terapias dirigidas.
- Diseño de ensayos clínicos y análisis de resultados en cáncer avanzado.
Sus Antecedentes
- El cáncer de pulmón de células pequeñas (SCLC) sigue siendo un tumor neuroendocrino significativo asociado al tabaco, con resultados históricamente pobres y avances limitados en el tratamiento.
- El tratamiento estándar de primera línea con quimioterapia con etoposida de platino ha mostrado un beneficio mínimo en la supervivencia, con la mayoría de los pacientes presentando una enfermedad en estadio extenso.
- Las ganancias incrementales anteriores se observaron con la radioterapia y la irradiación craneal profiláctica, pero se necesitaba un cambio de paradigma.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...